share_log

Sensei Biotherapeutics Slashes Workforce, Closes R&D Site

Benzinga Real-time News ·  Dec 8, 2022 10:41
  • Sensei Biotherapeutics Inc (NASDAQ:SNSE) announced a streamlining and realignment of resources.
  • The company will close its Boston research site and reduce its workforce by approximately 40% to extend Sensei's estimated cash runway into the second half of 2025 versus Q1 of 2025 expected earlier.
  • The company will maintain its Rockville, Maryland research facility, where antibody discovery and production in support of its lead program SNS-101 and other TMAb programs is conducted while maintaining a smaller business office in the Boston area.
  • With these announcements, Robert Pierce, Sensei's Chief R&D Officer, will move to a consulting role as a Science Fellow, and Edward van der Horst, Sensei's SVP, Biologics Discovery & Early Development, has been promoted to Chief Scientific Officer.
  • Sensei continues to advance SNS-101 through investigational new drug-enabling studies and intends to submit an Investigational New Drug application (IND) in or before April 2023.
  • Price Action: SNSE shares are down 2.60% at $1.50 on the last check Thursday.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment